Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01517945 · ClinicalTrials.gov registry record

Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study

A clinical trial of Breast Cancer and Rare Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
252
Enrollment target
1
Study location

NCT01517945: Active study of Breast Cancer and Rare Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT01517945 is a study of Breast Cancer and Rare Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 252 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01517945, a study of Breast Cancer and Rare Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
252 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test, customize, and personalize a mobile app-based intervention program in order to help rare and breast cancer survivors cope with fears of cancer recurrence.

Primary Outcome

This will involve development of a mobile app-based intervention program (based on our results from Phase 1 and 2 and preliminary work conducted by Beard et al.) that targets fear of cancer recurrence for breast, rare gynecological, rare melanoma and skin, long-term adult pediatric, and other rare cancer survivors.

Interventions

  • BEHAVIORAL AIM materials and assessments

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 252 participants
Start Date 2012-01
Est. Completion 2027-01
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT01517945 still lists

NCT01517945 is an observational study that tracks outcomes without assigning an intervention. The registered 252 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which AIM materials and assessments is the first listed.

NCT01517945 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01517945 about?

NCT01517945 is a clinical study titled "Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study". The purpose of this study is to test, customize, and personalize a mobile app-based intervention program in order to help rare and breast cancer survivors cope with fears of cancer recurrence.

What is the current status of trial NCT01517945?

This trial is currently active not recruiting. The enrollment target is 252 participants. The study started on 2012-01. Estimated completion is 2027-01.

What conditions does trial NCT01517945 study?

This clinical trial studies the following conditions: Breast Cancer, Rare Cancer.

What interventions are being tested in trial NCT01517945?

The interventions under investigation include: AIM materials and assessments (BEHAVIORAL).

Who is sponsoring clinical trial NCT01517945?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01517945 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01517945's enrollment target sits among peer trials

252 322nd of 1224 higher than 903 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02314988 · 252 participants · Phase 2

    Tranexamic Acid to Reduce Blood Loss in Spine Surgery

  • NCT03941756 · 252 participants · NA

    Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma

  • NCT05219617 · 252 participants · Phase 3

    Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

  • NCT05384158 · 252 participants · NA

    Valuation in Depressed Mood, Anhedonia, and Anxiety

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01517945, the US trial registry maintained by the National Library of Medicine. NCT01517945 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.